RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Matched conditions: RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Servier • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…
Matched conditions: RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC